: Maintains "Buy" rating on Hutchison China MediTech (00013.HK) - the all-new ATTC platform ignites innovation vitality.

According to the Wisdom Financial APP, Orient Securities released a research report predicting that the operating income of Hutchison Medicine (00013.HK) will be 600 million, 706 million, and 797 million US dollars respectively from 2025 to 2027. Based on comparable companies, the bank gives the company a 2026 5.29 times PS, corresponding to a target price of 33.29 Hong Kong dollars (exchange rate about 7.78), and maintains a "buy" rating. The company recently held a research and development day event, introducing the latest developments in cancer and immune disease treatment, including the new ATTC (next-generation antibody-targeted conjugate drugs) platform and pipeline situations.